The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prospective phase I study of checkpoint blockade for the treatment of patients with newly diagnosed high-grade glioma prior to radiochemotherapy: Results of nivolumab plus ipilimumab treatment arm.
 
Santosh Kesari
Stock and Other Ownership Interests - xCures
Honoraria - Jubilant Biosys; Pyramid Biosciences
Consulting or Advisory Role - Biocept; iCAD; xCures
Research Funding - AADi (Inst); AIVITA Biomedical, Inc. (Inst); Bavarian Nordic (Inst); Bayer (Inst); Biocept (Inst); Blue Earth Diagnostics (Inst); Boehringer Ingelheim (Inst); Caris MPI (Inst); CNS Pharmaceuticals (Inst); EpicentRx (Inst); Incyte (Inst); Lilly O. (Inst); Oblato (Inst); Orbus Therapeutics (Inst); Stemedica Cell Technologies (Inst)
 
Alexandre Wojcinski
No Relationships to Disclose
 
Jaya M. Gill
No Relationships to Disclose
 
Jose Arganda Carrillo
Research Funding - Nascent (Inst); Novocure (Inst)
 
Naveed Wagle
Research Funding - Bavarian Nordic (Inst); Bayer (Inst); Biocept (Inst); Boehringer Ingelheim (Inst); Caris MPI (Inst); CNS Pharmaceuticals (Inst); EpicentRx (Inst); Novocure (Inst); Oblato (Inst); Pyramid Biosciences (Inst); Stemedica Cell Technologies (Inst); xCures (Inst); Xoft (Inst)
 
Minhdan Nguyen
No Relationships to Disclose
 
Judy Dang Truong
No Relationships to Disclose
 
Tiffany M. Juarez
No Relationships to Disclose